uniQure N.V. SEC Filings

uniQure has a planned sale of ordinary shares under Rule 144. A person identified as Robert Gut filed to sell 25,613 ordinary shares through Citigroup Global Markets on the NASDAQ, with an aggregate market value of $676,695.00. The filing notes that there were 62,291,663 ordinary shares outstanding at the time, providing context for the sale size.

The shares to be sold include stock acquired on January 12, 2026 through a stock option exercise and sale pursuant to a Rule 10b5-1 trading plan, as well as vested share awards originally received in 2021 and 2022 as compensation from uniQure entities. The notice also discloses that Gut sold 31,434 ordinary shares on November 6, 2025 for gross proceeds of $856,881.00, as part of the required three-month sale history.

uniQure insider plans stock sale under Rule 144

A holder of uniQure N.V. ordinary shares filed a notice of proposed sale under Rule 144 for 6,390 ordinary shares, to be handled through Citigroup Global Markets, Inc. on the NASDAQ exchange. The filing lists an aggregate market value of $174,330.00 for these shares and notes that 62,291,663 ordinary shares were outstanding. The shares are described as acquired through a stock options exercise and sale pursuant to a Rule 10b5-1 trading plan, with cash as the form of payment. The notice also reports that Jack Kaye sold 38,810 ordinary shares during the past three months for $1,177,517.00 in gross proceeds.

uniQure N.V. filed a current report describing a communication milestone with U.S. regulators. On January 9, 2026, the company announced via press release that a Type A meeting with the U.S. Food and Drug Administration has been scheduled. This type of meeting is typically used to discuss important regulatory issues for a product or development program. The press release with further details is included as Exhibit 99.1 and is treated as information that is furnished, not filed, under securities law.

uniQure N.V. (QURE) disclosed insider transactions by a director on a Form 4 dated 11/06/2025. The reporting person exercised stock options for 15,840 ordinary shares at an exercise price of $4.57 (code M), then reported two open-market sales (code S): 15,840 shares at a weighted average price of $27.22 and 15,594 shares at $27.30. Following these transactions, 40,145 shares were beneficially owned directly.

The transactions were effected under a Rule 10b5-1 plan adopted on July 8, 2025. The filing notes footnote adjustments to prior reported holdings, and states the first sale’s weighted average reflects multiple trades between $27.00 and $27.38. The option covered 15,840 underlying shares, vested in full on June 19, 2025, and carries an expiration date of 06/19/2034.

uniQure (QURE) filed its Q3 2025 10‑Q, reporting wider losses but a much stronger cash position. Total revenues were $3.7 million, up from $2.3 million a year ago, driven by license revenue. Net loss was $80.5 million, compared to $44.4 million, as R&D and SG&A expenses increased and royalty‑financing interest remained sizable.

Liquidity improved materially: cash and cash equivalents were $597.1 million as of September 30, 2025. The company completed follow‑on offerings in January/February and September, receiving net proceeds of $70.1 million, $10.4 million, and $323.7 million, respectively; September included pre‑funded warrants to purchase 0.5 million shares and a $30.7 million related liability at quarter‑end. Liability from the HEMGENIX royalty financing was $469.1 million.

Debt was refinanced under a Hercules facility maturing October 1, 2030, with $50.0 million drawn and up to $100.0 million more available upon a Biologics License Application (BLA) approval for AMT‑130 prior to June 15, 2027. The company reported positive AMT‑130 Phase I/II topline data; however, following an October pre‑BLA meeting, the FDA feedback indicates the external‑control data may not be adequate as primary evidence, making BLA timing unclear. Ordinary shares outstanding were 62,165,900 as of September 30, 2025.

uniQure N.V. (QURE) furnished a press release announcing financial results for the quarter ended September 30, 2025 and provided a corporate update. The release is included as Exhibit 99.1 to a Form 8-K dated November 10, 2025.

The company states the information furnished under Item 2.02, including Exhibit 99.1, is not deemed “filed” under the Exchange Act. uniQure’s ordinary shares trade on the Nasdaq Global Select Market under the symbol QURE.

uniQure N.V. (QURE) disclosed that a director executed option exercises and same‑day sales on 11/04/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.

The director exercised 10,000 options at $7.37, 11,000 at $5.37, and 17,810 at $14.08, then sold equivalent ordinary shares at weighted average prices of $30.36, $30.34, and $30.33, respectively. Following these transactions, the director beneficially owned 20,439 ordinary shares, held directly.

uniQure reported a regulatory setback for AMT-130, its investigational gene therapy for Huntington’s disease. Following a pre-BLA meeting, the company believes the FDA currently no longer agrees that data from its Phase I/II studies, analyzed against an external control per prespecified protocols and statistical plans, may be adequate as primary evidence for a BLA.

As a result, the timing of the BLA submission for AMT-130 is now unclear. The update was announced on November 3, 2025 via a press release furnished as an exhibit. The disclosure highlights risks common to early-stage gene therapies, including evolving regulatory views on endpoints and comparators, and the potential need for additional clinical evidence.

uniQure N.V. entered into an underwriting agreement for an upsized public equity offering, selling 5,789,473 ordinary shares at $47.50 per share and issuing pre-funded warrants to purchase up to 526,316 additional ordinary shares. The underwriters exercised in full a 30-day option to buy up to 947,368 additional ordinary shares at the public offering price less underwriting discounts and commissions.

The company expects to receive approximately $323.75 million in net proceeds after underwriting discounts and estimated expenses. The pre-funded warrants are exercisable at any time after issuance but include beneficial ownership limits of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ prior notice. The securities are being offered under an automatically effective shelf registration, with closing expected on or about September 29, 2025 subject to customary conditions.